An earlier version of this live blog misstated the start date for Ziopharm's planned phase III drug study. It will start in mid-2010, not mid-2011. TheStreet regrets the error.

CHICAGO ( TheStreet) -- Welcome to TheStreet's live-blog coverage of the American Society of Clinical Oncology (ASCO) annual meeting. It's Monday, which means the big focus will be on how ASCO-related stocks react once trading opens.

Sunesis Pharmaceuticals ( SNSS), Ziopharm Oncology ( ZIOP) and Cyclacel Pharmaceuticals ( CYCC) will be among the companies also presenting data today.

Follow this live blog throughout the day for continuous updates and reports from the ASCO meeting. I'll be reporting on clinical data presentations as I see and hear them, and I'll be blogging from the hallways, exhibition hall and meeting rooms, giving you a real-time perspective on all the investor-worthy buzz. With my iPhone and some nifty software, I'll even try to bring you photos and audio for an even deeper perspective of what's happening at ASCO 2010.

I welcome your comments and questions on this live blog, too, which I'll do my best to answer and publish as time permits. You can also follow my ASCO 2010 coverage on Twitter.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

Insider Trading Alert - PODD, POWI And SNSS Traded By Insiders

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

Analysts' Actions -- Cigna, Monster Beverage, Qualcomm and More

Analysts' Actions -- Cigna, Monster Beverage, Qualcomm and More